Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01267253 · ClinicalTrials.gov registry record · Phase 2
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 20
- Study locations
NCT01267253: Completed Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by Gynecologic Oncology Group.
NCT01267253 is a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 31 participants, below the 122-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01267253, a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Primary Outcome
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Brivanib Alaninate
Study Locations (20)
Illinois
- Rush University Medical Center - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
- Sudarshan K Sharma MD Limited-Gynecologic Oncology - Hinsdale
Michigan
- Michigan Cancer Research Consortium NCORP - Ann Arbor
- Saint Joseph Mercy Hospital - Ann Arbor
- Saint Mary Mercy Hospital - Livonia
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- UCSF Medical Center-Mount Zion - San Francisco
Connecticut
- Smilow Cancer Hospital Care Center at Saint Francis - Hartford
- The Hospital of Central Connecticut - New Britain
Delaware
- Beebe Medical Center - Lewes
- Christiana Care Health System-Christiana Hospital - Newark
Florida
- Florida Hospital Orlando - Orlando
- Sarasota Memorial Hospital - Sarasota
Maryland
- Greater Baltimore Medical Center - Baltimore
- Union Hospital of Cecil County - Elkton
Arizona
- Saint Joseph's Hospital and Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-04-04 |
| Est. Completion | 2014-02-28 |
| Phase | Phase 2 |
What the finished NCT01267253 record still lists
NCT01267253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 122-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (75% lower).
The record links to 5 conditions, with Cervical Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01267253 names 20 study sites across 11 states, led by Illinois, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT01267253 about?
NCT01267253 is a clinical study titled "Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer". This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
What is the current status of trial NCT01267253?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-04-04. Estimated completion is 2014-02-28.
What conditions does trial NCT01267253 study?
This clinical trial studies the following conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease.
What interventions are being tested in trial NCT01267253?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Brivanib Alaninate (DRUG).
Who is sponsoring clinical trial NCT01267253?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01267253 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01267253's enrollment target sits among peer trials
31 11th of 13 higher than 3 of 13 other Cervical Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 2
-
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
COMPLETED · Phase 2
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI